The metalloprotease ADAMTS-5 is considered a potential target for the treatment of
osteoarthritis. To identify selective inhibitors of ADAMTS-5, we employed encoded library …

The aggrecan degrading metalloprotease ADAMTS-4 has been identified as a novel
therapeutic target for osteoarthritis. Here, we use DNA-encoded Library Technology (ELT) to …

There are currently no approved disease-modifying osteoarthritis (OA) drugs (DMOADs).
The aggrecanase ADAMTS-5 is key in the degradation of human aggrecan (AGC), a …

Objective A disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) is a
key enzyme in degradation of cartilage in osteoarthritis (OA). We report the pharmacological …

Summary Objective/Method Aggrecanase activity, most notably ADAMTS-5, is implicated in
pathogenic cartilage degradation. Selective monoclonal antibodies (mAbs) to both ADAMTS …

Summary Introduction Matrix metalloproteinases (MMPs) and 'aggrecanase'a disintegrin
and metalloproteinase with thrombospondin motifs (ADAMTSs) are well established to play …

Objective To determine the role of the proteinase ADAMTS‐1 in normal and accelerated
catabolism of aggrecan in articular and growth plate cartilage of mice. Methods Expression …

ADAMTS5 is involved in the pathogenesis of OA. As the major aggrecanase-degrading
articular cartilage matrix, ADAMTS5, has been regarded as a potential target for OA …

Objective To compare induction of the aggrecanases (ADAMTS‐1, ADAMTS‐4, ADAMTS‐5,
ADAMTS‐8, ADAMTS‐9, and ADAMTS‐15) by interleukin‐1β (IL‐1β) and tumor necrosis …

Degradation of proteoglycan is the key early event in the development of osteoarthritis (OA).
The aggrecanase ADAMTS-5 has been identified as the major enzyme responsible for the …